Background: It has been demonstrated that the pro-inflammatory cytokine macrophage migration inhibitory factor (MIF), which has chemokine-like properties, is a key player in a number of acute and long-term inflammatory disorders. However, nothing is known regarding the application of MIF as an inflammatory pathway marker in tuberculosis patients. The purpose of this study was to look at the relationship between MIF and IFN- and TNF-( relationship of MIF with IFN and TNF) in active pulmonary tuberculosis after anti-tuberculosis medication.
Methods: By using cytokine-specific ELISA, the serum levels of MIF, TNF, and IFN were assessed in 40 patients with APTB at four different times: at baseline, 3, 5, and 7 months after starting anti-tuberculosis medication. Additionally, we assessed the serum levels of MIF, TNF, and IFN in 40 healthy controls.
Results: Prior to the procedure, MIF serum levels were substantially higher (P
Key words: TNF-α, Macrophage migration inhibitory factor, Active pulmonary tuberculosis, IFN-γ
|
Download PDF 
Post
